Trial Profile
A Phase II Clinical Study of Chidamide as Maintenance Therapy in Responding Patients With Peripheral T-cell Lymphoma Treated With First-Line Chemotherapy
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2018
Price :
$35
*
At a glance
- Drugs Tucidinostat (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 13 Jul 2018 New trial record